NASDAQ : LABT
Lakewood-Amedex Biotherapeutics, Inc. — Financial statements
Healthcare · Biotechnology · United States
Last price 0.2 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 473.94K
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
Income statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | |
|---|---|---|---|---|
| Selling, General & Admin | 5.64M | 2.51M | 1.92M | 3.10M |
| Research & Development | 1.62M | 1.26M | 2.10M | 5.53M |
| Operating Expenses | 7.27M | 3.77M | 4.03M | 8.64M |
| Operating Income | -7.27M | -3.77M | -4.03M | -8.64M |
| Interest Expense | -124.47K | -100.88K | -5.00K | -10.00K |
| Interest & Investment Income | 45.28K | 25.61K | 142.60K | 360.12K |
| Other Non Operating Income (Expenses) | 600.00 | 77.00K | 4.64K | |
| EBT Excluding Unusual Items | -7.35M | -3.85M | -3.81M | -8.28M |
| Gain (Loss) on Sale of Investments | -722.00 | |||
| Other Unusual Items | -1.04M | |||
| Pretax Income | -7.35M | -3.85M | -4.86M | -8.28M |
| Net Income | -7.35M | -3.85M | -4.86M | -8.28M |
| Preferred Dividends & Other Adjustments | 1.63M | 2.00M | 2.00M | |
| Net Income to Common | -8.97M | -5.85M | -6.86M | -8.28M |
| Shares Outstanding (Basic) | 879.90K | 696.27K | 690.91K | 681.08K |
| Shares Outstanding (Diluted) | 879.90K | 696.27K | 690.91K | 681.08K |
| EPS (Basic) | -10.20 | -8.40 | -9.92 | -12.16 |
| EPS (Diluted) | -10.20 | -8.40 | -9.92 | -12.16 |
| Free Cash Flow | -3.49M | -1.94M | -5.73M | -6.82M |
| Free Cash Flow Per Share | -3.96 | -2.79 | -8.29 | -10.01 |
| EBITDA | -7.26M | -3.77M | -4.02M | -8.63M |
| D&A For EBITDA | 4.63K | 4.63K | 6.30K | 11.56K |
| EBIT | -7.27M | -3.77M | -4.03M | -8.64M |
Balance sheet
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | |
|---|---|---|---|---|
| Cash & Equivalents | 2.58M | 236.40K | 681.10K | 2.53M |
| Short-Term Investments | 2.00M | 3.86M | ||
| Cash & Short-Term Investments | 4.58M | 236.40K | 681.10K | 6.39M |
| Prepaid Expenses | 256.00K | 68.99K | 92.88K | 90.09K |
| Total Current Assets | 4.85M | 305.39K | 773.98K | 6.48M |
| Property, Plant & Equipment | 106.89K | 168.08K | 288.05K | 404.80K |
| Other Long-Term Assets | 7.82K | 8.13K | 8.55K | 8.55K |
| Total Assets | 4.96M | 481.60K | 1.07M | 6.89M |
| Accounts Payable | 165.94K | 381.04K | 166.47K | 499.07K |
| Accrued Expenses | 361.37K | 404.75K | 221.64K | 1.26M |
| Short-Term Debt | 1.50M | 200.00K | ||
| Current Portion of Leases | 101.62K | 119.31K | 112.52K | 106.02K |
| Total Current Liabilities | 628.93K | 2.41M | 500.63K | 2.06M |
| Long-Term Leases | 41.03K | 160.34K | 272.86K | |
| Total Liabilities | 628.93K | 2.45M | 660.97K | 2.34M |
| Common Stock | 217.00 | 704.00 | 699.00 | 686.00 |
| Additional Paid-In Capital | 73.12M | 51.53M | 50.06M | 49.30M |
| Retained Earnings | -68.64M | -53.35M | -49.50M | -44.65M |
| Treasury Stock | -150.00K | -150.00K | -150.00K | -100.00K |
| Total Common Equity | 4.33M | -1.97M | 406.57K | 4.56M |
| Shareholders' Equity | 4.33M | -1.96M | 409.61K | 4.56M |
| Total Liabilities & Equity | 4.96M | 481.60K | 1.07M | 6.89M |
| Total Debt | 101.62K | 1.66M | 272.86K | 578.88K |
| Net Cash (Debt) | 4.48M | -1.42M | 408.24K | 5.81M |
| Net Cash Per Share | 5.10 | -2.05 | 0.59 | 8.53 |
| Filing Date Shares Outstanding | 2.37M | 699.55K | 694.34K | 681.08K |
| Total Common Shares Outstanding | 2.17M | 699.55K | 694.35K | 681.08K |
| Working Capital | 4.22M | -2.10M | 273.35K | 4.42M |
| Book Value Per Share | 2.00 | -2.81 | 0.59 | 6.69 |
| Tangible Book Value | 4.33M | -1.97M | 406.57K | 4.56M |
| Tangible Book Value Per Share | 2.00 | -2.81 | 0.59 | 6.69 |
| Machinery | 77.40K | 77.40K | 75.56K |
Cash flow statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | |
|---|---|---|---|---|
| Net Income | -7.35M | -3.85M | -4.86M | -8.28M |
| Depreciation & Amortization | 121.57K | 119.98K | 118.59K | 120.98K |
| Loss (Gain) From Sale of Investments | -65.80K | -76.52K | ||
| Stock-Based Compensation | 3.79M | 1.35M | 269.67K | 608.24K |
| Change in Accounts Payable | 86.42K | 214.57K | -332.60K | 54.37K |
| Change in Other Net Operating Assets | -138.69K | 214.90K | -857.78K | 758.77K |
| Operating Cash Flow | -3.49M | -1.94M | -5.72M | -6.82M |
| Capital Expenditures | -1.85K | |||
| Investment in Securities | -2.00M | 3.93M | -3.78M | |
| Investing Cash Flow | -2.00M | 3.92M | -3.78M | |
| Short-Term Debt Issued | 1.50M | |||
| Total Debt Issued | 198.16K | 1.50M | ||
| Net Debt Issued (Repaid) | 1.50M | |||
| Repurchase of Common Stock | -50.00K | |||
| Financing Cash Flow | 6.80M | 1.50M | -50.00K | |
| Net Cash Flow | 1.32M | -444.70K | -1.85M | -10.60M |
| Free Cash Flow | -3.49M | -1.94M | -5.73M | -6.82M |
| Free Cash Flow Per Share | -3.96 | -2.79 | -8.29 | -10.01 |
| Levered Free Cash Flow | -911.36K | -525.74K | -3.50M | |
| Unlevered Free Cash Flow | -833.56K | -462.69K | -3.50M | |
| Cash Interest Paid | 993.00 | |||
| Change in Working Capital | -52.27K | 429.47K | -1.19M | 813.15K |
Ratios
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | |
|---|---|---|---|---|
| Debt / Equity Ratio | 0.02 | -0.84 | 0.67 | 0.13 |
| Net Debt / Equity Ratio | -1.03 | -0.72 | -1.00 | -1.27 |
| Net Debt / EBITDA Ratio | 0.62 | -0.38 | 0.10 | 0.67 |
| Net Debt / FCF Ratio | 1.29 | -0.73 | 0.07 | 0.85 |
| Quick Ratio | 7.29 | 0.10 | 1.36 | 3.10 |
| Current Ratio | 7.70 | 0.13 | 1.55 | 3.14 |
| Return on Equity (ROE) | -402.83% | -195.47% | ||
| Return on Assets (ROA) | -139.40% | -303.80% | -63.20% | |
| Return on Capital Employed (ROCE) | -167.80% | 196.10% | -706.50% | -178.80% |
| Buyback Yield / Dilution | -27.02% | -0.78% | -1.44% |